APA (7th ed.) Citation

Jiang, Y., Bei, W., Wang, L., Lu, N., Xu, C., Liang, H., . . . Liu, G. Efficacy and safety of cadonilimab (PD-1/CTLA-4 bispecific) in combination with chemotherapy in anti-PD-1-resistant recurrent or metastatic nasopharyngeal carcinoma: A single-arm, open-label, phase 2 trial. BMC.

Chicago Style (17th ed.) Citation

Jiang, Yaofei, et al. Efficacy and Safety of Cadonilimab (PD-1/CTLA-4 Bispecific) in Combination with Chemotherapy in Anti-PD-1-resistant Recurrent or Metastatic Nasopharyngeal Carcinoma: A Single-arm, Open-label, Phase 2 Trial. BMC.

MLA (9th ed.) Citation

Jiang, Yaofei, et al. Efficacy and Safety of Cadonilimab (PD-1/CTLA-4 Bispecific) in Combination with Chemotherapy in Anti-PD-1-resistant Recurrent or Metastatic Nasopharyngeal Carcinoma: A Single-arm, Open-label, Phase 2 Trial. BMC.